APPENDIX E1. Expanded statistical analysis methods

and results.

Analysis of covariance using the rank transformation¹¹ was performed to adjust for covariates. In the ranked analysis of covariance models, candidate covariates included the 4 levels of stratification at randomization (known coronary disease as binary, time of day of presentation 6 AM to 3 PM or 3 PM to 6 AM), age (continuous and binary as \geq 65 years), TIMI risk score, sex, race, confirmed previous heart failure, confirmed previous MI, confirmed previous coronary revascularization, and chest pain at ED arrival. First, interactions between treatment group and each covariate were examined. One significant interaction was present between aged 65 years or older and treatment group but not included in the final model because its effect had a quantitative effect only and complicated the interpretation of the main effects of the model. The 4 stratification levels were then entered into the models. Confounding was evaluated by comparing the effect of treatment group between the full and reduced models. In the full model, the observation unit–cardiac MRI rank reduction was 18.5 (P<.001); in the reduced model, the observation unit–cardiac MRI rank reduction was 22.4 (P<.001). The full model is displayed in Table E3. For hypothesis-generation purposes, post hoc subgroup analyses were conducted and reported in Table E4.

Table E1. Typical cardiac imaging parameters.

Component	Pulse Sequence	Orientation	Matrix	FOV, mm	Slice Thickness, mm	Flip Angle, degrees	Bandwidth, Hz/Pixel	TE, ms	TR, ms
Resting wall motion	trueFISP	2-, 3-, And 4-chamber and 3 LV short-axis views	192×156	340	8	75	930	1	≈47
T2 dark blood (body coil)	IR turboSE 650 ms TI	3 LV short-axis views	192×140	360	7	60	180	87	1 RR
Contrast injection (g	adopentetate dimeglu	mine 0.1 mmol/kg) and	stress agen	t infusio	n (adenosine)			
Stress perfusion	Turbo-FLASH	3 LV short-axis views	192×144	360	8	12	650	1	\approx 190
Contrast injection (g	adopentetate dimeglu	mine 0.1 mmol/kg)							
Rest perfusion	Turbo-FLASH	3 LV short-axis views	192×144	360	8	12	650	1	≈190
Delayed enhancement	FLASH IR 300-ms TI	2-, 3-, And 4-chamber and 10 short-axis views	192×140	320	8	25	1,530	2	2 RR

FOV, Field of view; TE, echo time; TR, pulse repetition time; LV, left ventricle; IR, inversion recovery; TI, inversion time; trueFISP, True fast imaging with steady state precession; SE, spin echo; FLASH, fast low angle shot.

Table E2. Imaging results for OU-CMR participants.*

	CMR Results		
	Inducible Ischemia	No Inducible Ischemia	
ACS	1	0	1
No ACS	5	43	48
Total	6	43	49

*Sensitivity 100% (95% CI 3% to 100%); specificity 90% (95% CI 77% to 97%). Stress agent: adenosine 43 of 49; dobutamine 6 of 49.

Table E3. Median cost among subgroups and adjustedstatistical significance from the full model.

Subgroup Name	Number of Participants	Median Cost, %	Adjusted <i>P</i> Value	
Treatment group			.003	
Inpatient care	53	2,680		
OU-CMR	57	2,062		
Age, y			.93	
≥65	18	2,607		
<65	92	2,383		
Age, y (continuous)	110	N/A	.50	
TIMI risk score (continuous)	110	N/A	.69	
Sex			.37	
Male	55	2,559		
Female	55	2,250		
Race			.18	
Caucasian	75	2,551		
Other	35	2,243		
Time of presentation			.33	
6 ам–З рм	90	2,388		
З РМ-6 АМ	20	2,507		
Established CAD			.58	
Established CAD	28	2,606		
No established CAD	82	2,342		
Previous heart failure (confirmed)			.04	
Previous heart failure	5	3,159		
No previous heart failure	105	2,357		
Previous MI (confirmed)			.46	
Previous MI	22	2,644		
No previous MI	88	2,310		
Previous revascularization			.26	
(confirmed)				
Previous revascularization	24	2,606		
No previous revascularization	86	2,342		
Chest pain at ED arrival			.03	
Chest pain	76	2,635		
No chest pain	34	2,088		

Table E4. Post hoc subgroup analyses of median cost by subgroup.

	Conventional Care			OU-CMR		
Subgroup Name	No.	Cost, \$	No.	Cost, \$	<i>P</i> Value	
Age, y						
≥65	10	2,661	8	2,114	.003	
<65	47	3,250	45	1,985	.014	
Sex						
Male	30	2,742	25	2,150	.12	
Female	27	2,662	28	2,043	<.001	
Race						
Caucasian	40	2,799	35	2,062	.002	
Other	17	2,636	18	2,090	.092	
Time of presentation						
6 ам–З рм	46	2,674	44	2,057	.003	
З РМ-6 АМ	11	2,707	9	2,129	.047	
Established CAD						
Established CAD	16	3,212	12	2,079	.030	
No established CAD	41	2,661	41	2,062	.007	
Previous heart failure						
(confirmed)						
Previous heart failure	3	2,661	2	5,296	.79	
No previous heart failure	54	2,693	51	2,051	<.001	
Previous revascularization						
(confirmed)						
Previous	15	3,068	9	2,044	.023	
revascularization						
No previous	42	2,664	44	2,088	.006	
revascularization						